Search

Your search keyword '"Cotte, L"' showing total 531 results

Search Constraints

Start Over You searched for: Author "Cotte, L" Remove constraint Author: "Cotte, L"
531 results on '"Cotte, L"'

Search Results

1. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

3. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.

7. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

10. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

11. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France

12. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

13. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

14. Uvéites chez les patients vivant avec le VIH : une étude rétrospective multicentrique

15. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

16. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

17. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy

18. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

19. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

20. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

23. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)

24. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study

25. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission

26. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

27. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

34. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz

35. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

36. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse : a post-hoc analysis of the ANRS IPERGAY trial

37. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

38. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

41. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial

42. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

43. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

46. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

49. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France

50. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

Catalog

Books, media, physical & digital resources